Update on hepatitis B and C coinfection in HIV

Current Infectious Disease Reports

Volumn 7, Issue 4, 2005, Pages 299-308

  Yachimski, Patrick ^b   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA2A INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; DIDANOSINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INSOMNIA; LACTATE BLOOD LEVEL; LEUKOPENIA; LIVER DISEASE; MENTAL DISEASE; META ANALYSIS; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; REVIEW; SERODIAGNOSIS; SUPERINFECTION; THROMBOCYTOPENIA; VIRUS RESISTANCE;

EID: 23844550538     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0063-4     Document Type: Review

References (88)

1. Sheng WH, Chen MY, Hsieh SM, et al.: Impact of chronic hepatitis B virus (HBV) on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004, 38:1471-1477.
2. Kellerman SE, Hanson DL, McNaghten D, Fleming PL: Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:571-577.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831-837.
4. Staples CT, Rimland D, Dudas C: Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veteran Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
5. Thio CL, Seaberg EC, Skolasky R, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
6. Darby SC, Ewart DW, Giangrande PLF, et al.: Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997, 350:1425-1431.
7. Ragni MV, Belle SH: Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001, 183:1112-1115.
8. Monga HK, Rodriguez-Barradas MC, Breaux K, et al.: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 33:240-247.
9. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054-1058.
10. Puoti M, Bonancini M, Spinetti A, et al.: Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001, 183:134-137.
11. Graham CS, Curry M, He Q, et al.: Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004, 40:125-132.
12. Kuntzen T, Tural C, Pujol T, et al.: Intrahepatic cytokine and chemokine mRNA expression in HCV and HIV/HCV coinfection [abstract]. Hepatology 2004, 40(Suppl 1):406A.
13. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patient with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
14. Sabin CA, Telfer P, Phillips AN, et al.: The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophiliac men. J Infect Dis 1997, 175:164-168.
15. Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
16. Chung RT, Evans SP, Yang Y, et al.: Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002, 16:1915-1923.
17. Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
18. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003, 362:1708-1713.
19. Chung RT, Kim AY, Polsky B: HIV/hepatitis B and C coinfection: pathogeneic interactions, natural history and therapy. Antivir Chem Chemother 2001, 12(Suppl 1):73-91.
20. Perrillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
21. Cooper S, Erickson AL, Adams EJ, et al.: Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10:439-449.
22. Lechner F, Wong DKH, Dunbar PR, et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191:1499-1512.
23. Lauer GM, Nguyen TN, Day CL, et al.: Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002, 76:2817-2826.
24. Lascar RM, Gilson RJ, Lopes AR, et al.: Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. J Infect Dis 2003, 188:1815-1819.
25. Carr A, Cooper DA: Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:995-996.
26. Velasco M, Moran A, Tellez MJ: Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999, 340:1765-1766.
27. Zylberberg H, Pialoux G, Carnot F, et al.: Rapidly evolving hepatitis C virus-related cirrhosis in a human immuno-deficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255-1258.
28. Vento S, Garofano T, Renzini C, et al.: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998, 12:116-117.
29. John M, Flexman J, French M: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289-2293.
30. Fialaire P, Payan C, Vitour D, et al.: Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999, 180:574-575.
31. Ranieri R, Santambrogio C, Veronelli A, Pontiroli AE: Hepatitis C viremia persistently suppressed by HAART. Clin Infect Dis 2003, 36:1086-1087.
32. Yokozaki S, Takamatsu J, Nakano I, et al.: Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000, 96:4293-4299.
33. Rutschmann OT, Negro F, Hirschel B, et al.: Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998, 177:783-785.
34. Zylberberg H, Chaix ML, Rabian C, et al.: Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998, 26:1104-1106.
35. Garcia-Samaniego J, Bravo R, Castilla J, et al.: Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998, 28:526-527.
36. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
37. Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing anti-retroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
38. Gandhi RT, Wurcel A, McGovern B, et al.: Low prevalence of ongoing hepatitis B viremia in HIV-positive persons with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003, 34:439-441.
39. Piroth L, Binquet C, Vergne M, et al.: The evolution of hepatitis B virus serologic patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002, 36:681-686.
40. Hofer M, Joller-Jemelka JI, Grob PJ, et al.: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998, 17:6-13.
41. Takaki A, Wiese M, Maertens G, et al.: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578-582.
42. Lok ASF, McMahon BJ: AASLD Practice Guidelines: Chronic Hepatitis B. http://www.aasld.org/eweb/docs/chronichep_B.pdf. Accessed February 23, 2005.
43. Masur H, Kaplan JE, Holmes KK: Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002, 137:435-478.
44. Krain A, Wisnivesky JP, Garland E, McGinn T: Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection. Mayo Clin Proc 2004, 79:51-56.
45. Gordon SC, Veneri RJ, McFadden RF, et al.: Major hemorrhage after percutaneous liver biopsy in patients with AIDS. Gastroenterology 1991, 100:1787.
46. Soriano V, Garcia-Samaniego J: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials 2002, 3:351-353.
47. Fultz SL, Justice AC, Butt AA, et al.: Testing, referral, and treatment patterns for HCV coinfection in a cohort of veterans with HIV infection. Clin Infect Dis 2003, 36:1039-1046.
48. Myers RP, Benhamou Y, Imbert-Bismut F, et al.: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003, 17:751-753.
49. Di Martino V, Thevenot T, Colin JF, et al.: Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002, 123:1812-1822.
50. Benhamou Y, Katlama C, Lunel F, et al.: Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996, 125:705-712.
51. Dore GJ, Cooper DA, Barrett C, et al.: Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999, 180:607-613.
52. Fang CT, Chen PJ, Hung CC, et al.: Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 2003, 39:1028-1035.
53. Benhamou Y, Bochet M, Thibault V, et al.: Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999, 20:1302-1306.
54. Ripamonti D, Maggiolo F, Suter F: HIV-1 and hepatitis B virus: time for a re-think? Lancet 2004, 363:1400.
55. Lok AS, Heathcote EJ, Hooffnagle JH: Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001, 120:1828-1853.
56. Benhamou Y, Thibault V, Calvez V, et al.: 3-year treatment with adefovir dipivoxil in chronic hepatitis B patients with lamivudine-resistant HBV/HIV co-infection results in significant and sustained clinical improvement [abstract 835]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
57. Angus P, Vaughn R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
58. Xiong S, Yang H, Westland CE, et al.: Resistance surveillance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV) [abstract]. J Hepatol 2003, 38(Suppl 2):182.
59. Westland CE, Yang H, Delaney WE, et al.: Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy [abstract]. J Hepatol 2003, 38(Suppl 2):182.
60. Brook M, Gilson R, Wilkins E: BHIVA Guidelines for Treatment and Management of HIV and Hepatitis B Coinfection. http://www.bhiva.org/guidelines/2004/HBV/index.html. Accessed February 23, 2005.
61. Valla DC: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland, Consensus statement (short version). J Hepatol 2003, 38:533-540.
62. Delaugerre C, Marcelin AG, Thibault V, et al.: Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002, 46:1586-1588.
63. Hannon H, Bagnis CI, Benhamou Y, et al.: The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant persons coinfected with hepatitis B and HIV. Nephrol Dial Transplant 2004, 19:386-390.
64. Izzedine H, Hulet JS, Launay-Vacher V, et al.: Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66:1153-1158.
65. Ying C, De Clercq E, Nicholson W, et al.: Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Virol Hepatol 2000, 7:161-165.
66. Lada O, Benhamou Y, Cahour A, et al.: In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004, 9:353-363.
67. van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421-1425.
68. Dore GJ, Cooper DA, Pozniak AL, et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral-therapy-naïve and - experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189:1185-1192.
69. Pessoa W, Gazzard B, Huang A, et al.: Entecavir in HIV/HBV-coinfected patients: safety and efficacy in a phase II study (ETV-038) [abstract 123]. Programs and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25, 2005.
70. Nunez M, Puoti M, Camino N, Soriano V: Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 2003, 37:1678-1685.
71. Zylberberg H, Benhamou Y, Lagneaux JL, et al.: Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000, 47:694-697.
72. Nasti G, Di Gennaro G, Tavio M, et al.: Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001, 15:1783-1787.
73. Landau A, Batisse D, Piketty C, et al.: Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001, 15:2149-2155.
74. Sauleda S, Juarez J, Esteban JI, et al.: Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected subjects with congenital coagulation disorders. Hepatology 2001, 34:1035-1040.
75. Brau N, Rodriguez-Torres M, Prokupek D, et al.: Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full course vs. 16-week delayed ribavirin. Hepatology 2004, 39:989-998.
76. Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
77. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
78. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
79. Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280-281.
80. Moreno A, Querada C, Moreno L, et al.: High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004, 9:133-138.
81. Shiffman MI, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164-1172.
82. Lo Re V III, Kostman JR: Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Read 2004, 14:555-571.
83. McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
84. Dieterich DT, Wasserman R, Brau N, et al.: Once-weekly epoietin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003, 98:2491-2499.
85. Afdhal NH, Dieterich DT, Pockros PJ, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302-1311.
86. Neff GW, Bonham A, Tzakis AG, et al.: Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003, 9:239-247.
87. Ragni MV, Belle SH, Im K, et al.: Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003, 188:1412-1420.
88. Ross AS, Bhan AK, Pascual M, et al.: Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004, 18:166-173.